What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes

Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). BRCA1/2 loss-of-function is linked to hereditary PCs and homologous recombination DNA-repair system defici...

Descripción completa

Detalles Bibliográficos
Autores principales: Palicelli, Andrea, Croci, Stefania, Bisagni, Alessandra, Zanetti, Eleonora, De Biase, Dario, Melli, Beatrice, Sanguedolce, Francesca, Ragazzi, Moira, Zanelli, Magda, Chaux, Alcides, Cañete-Portillo, Sofia, Bonasoni, Maria Paola, Ascani, Stefano, De Leo, Antonio, Giordano, Guido, Landriscina, Matteo, Carrieri, Giuseppe, Cormio, Luigi, Gandhi, Jatin, Nicoli, Davide, Farnetti, Enrico, Piana, Simonetta, Tafuni, Alessandro, Bonacini, Martina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868626/
https://www.ncbi.nlm.nih.gov/pubmed/35203446
http://dx.doi.org/10.3390/biomedicines10020236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8868626/
https://www.ncbi.nlm.nih.gov/pubmed/35203446
http://dx.doi.org/10.3390/biomedicines10020236

Ejemplares similares